Civic Intelligence

Path Drug Solutions

990 • Fiscal year 2015 • EIN 94-3384500

Jan 01, 2015 to Dec 31, 2015 • Filed on Nov 11, 2016

Organization ProfileWWW.PATH.ORG

View Organization Page

2201 Westlake Avenue No 200Seattle, WA 98121

(206) 285-3500

Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

35th percentile

0.11x

Higher debt load relative to assets than 35% of similar nonprofits.

2015 filings • 501(c)3 • $10M-$25M nonprofits • Source year 2015

Liabilities / Revenue

47th percentile

0.22x

Higher debt load relative to revenue than 47% of similar nonprofits.

2015 filings • 501(c)3 • $10M-$25M nonprofits • Source year 2015

Net Margin

76th percentile

16%

Higher net margin than 76% of similar nonprofits.

2015 filings • 501(c)3 • $10M-$25M nonprofits • Source year 2015

Top Officer Pay

93rd percentile

$666,767

Higher top officer pay than 93% of similar nonprofits.

Top officer pay equals 9.3% of source-year revenue.

2015 filings • 501(c)3 • $10M-$25M nonprofits • Source year 2015

Asset Growth

1st percentile

-61%

Faster asset growth than 1% of similar nonprofits.

2015 filings • 501(c)3 • $10M-$25M nonprofits • Annualized from 2014 to 2015

Revenue Growth

87th percentile

35%

Faster revenue growth than 87% of similar nonprofits.

2015 filings • 501(c)3 • $10M-$25M nonprofits • Annualized from 2014 to 2015

Balance Sheet
Liabilities / Assets35th percentile

Assets

Down

$14,847,024

Down $23,131,389 (-61%) from 2014

Net Assets

Down

$13,241,721

Down $23,152,000 (-64%) from 2014

Liabilities

Up

$1,605,303

Up $20,611 (+1.3%) from 2014

Revenue And Expenses
Liabilities / Revenue47th percentileNet Margin76th percentile

Revenue

Up

$7,139,715

Up $1,869,609 (+35%) from 2014

Expenses

Down

$5,997,711

Down $4,761,778 (-44%) from 2014

Net Income

Up

$1,142,004

Up $6,631,387 (+121%) from 2014

Historical Trend

Balance Sheet Trend

Asset Growth1st percentile

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$60M$40M$20M$0Assets 2010: $26,215,343Liabilities 2010: $4,437,688Net Assets 2010: $21,777,6552010Assets 2011: $24,285,254Liabilities 2011: $1,581,867Net Assets 2011: $22,703,3872011Assets 2012: $28,999,523Liabilities 2012: $2,883,967Net Assets 2012: $26,115,5562012Assets 2013: $42,859,417Liabilities 2013: $977,931Net Assets 2013: $41,881,4862013Assets 2014: $37,978,413Liabilities 2014: $1,584,692Net Assets 2014: $36,393,7212014Assets 2015: $14,847,024Liabilities 2015: $1,605,303Net Assets 2015: $13,241,7212015Assets 2016: $10,229,897Liabilities 2016: $46,385Net Assets 2016: $10,183,5122016Assets 2017: $7,105,262Liabilities 2017: $708,783Net Assets 2017: $6,396,4792017Assets 2018: $0Liabilities 2018: $0Net Assets 2018: $02018

Highlighted filing

2015

Assets$14,847,024
Liabilities$1,605,303
Net Assets$13,241,721
Open 2015 Filing

Operations Trend

Revenue Growth87th percentile

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$30M$20M$10M$0-$10MExpenses 2010: $17,804,3432010Expenses 2011: $13,676,7372011Expenses 2012: $11,651,8702012Revenue 2013: $24,724,025Expenses 2013: $8,958,738Net Income 2013: $15,765,2872013Revenue 2014: $5,270,106Expenses 2014: $10,759,489Net Income 2014: -$5,489,3832014Revenue 2015: $7,139,715Expenses 2015: $5,997,711Net Income 2015: $1,142,0042015Revenue 2016: $216,478Expenses 2016: $3,275,717Net Income 2016: -$3,059,2392016Revenue 2017: $201,146Expenses 2017: $2,548,179Net Income 2017: -$2,347,0332017Revenue 2018: $2,972,163Expenses 2018: $3,576,203Net Income 2018: -$604,0402018

Highlighted filing

2015

Revenue$7,139,715
Expenses$5,997,711
Net Income$1,142,004
Open 2015 Filing
Jump To
Filing Snapshot
Filing Period
Jan 1, 2015 to Dec 31, 2015
Signed
Nov 11, 2016
Return Version
2015v2.1
Gross Receipts
$7,143,163
Mission and Program Overview

Mission

Path drug solutions (pds) develops and advances safe and effective medicines for the prevention and treatment of diseases disproportionately affecting women and children in low-resource settings. We work with a variety of public- and private-sector stakeholders to build cross-sector collaborations, secure intellectual property, revisit promising drugs or drug candidates that have been set aside for nonmedical reasons (e.g., lack of earning potential), and harness scientific and manufacturing capacity in high- and low- or middle-income countries to ensure drugs are available, accessible, and affordable to all those who need them.

SEE PART III, LINE 1.

Balance Sheet Detail
LineBeginningEndChange
Assets
Savings and Temporary Cash Investments$25,840,796$12,733,112▼ $13,107,684
Pledges and Grants Receivable$12,038,366$2,045,216▼ $9,993,150
Cash and Non-Interest-Bearing Accounts$51,703$49,655▼ $2,048
Land, Buildings, and Equipment, Net$21,856$10,020▼ $11,836
Investments in Publicly Traded Securities$3,904$3,736▼ $168
Prepaid Expenses and Deferred Charges$21,081$3,352▼ $17,729
Accounts Receivable$707$1,933▲ $1,226
Total Assets$37,978,413$14,847,024▼ $23,131,389
Liabilities
Accounts Payable and Accrued Expenses$1,584,692$1,605,303▲ $20,611
Total Liabilities$1,584,692$1,605,303▲ $20,611
Net Assets / Fund Balance
Temporarily Rstr Net Assets$35,769,358$12,597,329▼ $23,172,029
Unrestricted Net Assets$624,363$644,392▲ $20,029
Total Net Assets Fund Balance$36,393,721$13,241,721▼ $23,152,000
Total Liabilities and Net Assets / Fund Balance$37,978,413$14,847,024▼ $23,131,389

Asset Categories

AssetBook ValueDepreciationBasis
Equipment$10,020$93,107$103,127
Compensation and Service Providers
Top Officer Pay93rd percentile

Board Members and Trustees

NameTitle
Stephen B DavisPresident & CEO
Dan HartmanDirector
David C KaslowDirector
Jorge FloresDirector
Keith ChirgwinDirector
Ken DuncanDirector
Daniel LasterSecretary
Olivia D PoliusTreasurer & CFO
Revenue and Support

Revenue Composition

Contributions and Grants
$7,126,779
Program Service Revenue
$0
Investment Income
$12,936
Other Revenue
$0
All Other Contributions
$6,310,419
Change in Net Assets
$1,142,004
Expenses and Functional Allocation

Major Expense Lines

Line ItemAmount
Grants and Similar Amounts Paid$4,768,944
Other Expenses$1,228,767
Professional Fundraising Fees$0
Salaries, Compensation, and Employee Benefits$0
Total Fundraising Expense$0

Functional Expense Allocation

Line ItemProgramManagementFundraisingTotal
Grants to Domestic Orgs$4,621,920--$4,621,920
Travel$368,381--$368,381
Occupancy-$182,552-$182,552
Foreign Grants$147,024--$147,024
Fees for Services Other$112,777$12,000-$124,777
Conferences and Meetings$57,763--$57,763
Office Expenses$54,471$144-$54,615
Insurance$7,249$1,676-$8,925
Depreciation Depletion-$6,706-$6,706
Fees for Services Legal$4,504--$4,504
Information Technology$3,207--$3,207
Other Expenses$1,468$1,550-$3,018
Advertising$1,789--$1,789
All Other Expenses$1,105--$1,105
Total Functional Expenses$5,792,785$204,926$0$5,997,711
International Activity

Grant and Assistance Recipients

RecipientLocationCategoryPurposeAmount
PathSeattle, WA501(c)(3)General Support$3,835,141
Clinton Health Access Initiative IncBoston, MA501(c)(3)Product Development$487,953
St Louis UniversitySt Louis, MO501(c)(3)Product Development$253,110
Yale UniversityNew Haven, CT501(c)(3)Product Development$45,692

International Summary

Offices
0
Employees
1
Spending
$619,342

International Compliance

Foreign grant records maintained
Yes
Activity in boycott countries
No
Foreign corporation ownership
No
Foreign partnership interest
No
Interest in foreign trust
No
Passive foreign investment company interest
No
Transfers to foreign corporations
Yes

International Activities

RegionActivityServicesOfficesEmployeesSpending
South AsiaProgram ServicesInternational Development00$276,841
EuropeProgram ServicesProduct Development00$188,556
South AsiaGrantmaking-00$147,024
East Asia and the PacificProgram ServicesProduct Development00$6,141
South AsiaProgram ServicesProduct Development01$780
Fundraising, Events, and Gaming
Fundraising activities
No
Gaming activities
No
Professional fundraiser used
No

Fundraising and Gaming Totals

Line ItemAmount
Professional Fundraising Fees$0
Political and Lobbying Activity
Political campaign activity
No
Lobbying activity
No
Subject to proxy tax
No
Governance and Compliance

Governance Checklist

Compiled or reviewed by an accountant
No
Annual disclosure for covered persons
Yes
Audit committee
Yes
Business relationship with family members
No
Business relationship with organization members
No
Material changes to governing documents
No
Compensation from other sources disclosed
No
CEO compensation reviewed
No
Other officer compensation reviewed
No
Conflict-of-interest policy
Yes
Audited financial statements prepared
Yes
Key decisions subject to board approval
No
Management duties delegated
No

Governance Explanations

Form 990, Part VI, Section B, Line 11

“The form 990 was prepared by an outside accounting firm (gelman, rosenberg & freedman) using information provided by path accounting services staff. Path senior management reviewed the draft form. A copy of the draft was sent to path's board of directors for comment. After the comment period, the chief financial officer signed and filed the return.”

Form 990, Part VI, Section B, Line 12C

“Pds has policies and procedures to address conflicts of interest. Path management and all staff above a designated level in the organization must complete a conflict of interest disclosure form each year. All forms are reviewed and kept on file. A conflict management plan is developed for any employee with a significant actual or perceived conflict of interest. Path also has a well-defined procedure for identifying and reporting actual and potential conflicts of interest among board members. New board members are asked to complete a conflict of interest disclosure form within 30 days of joining the board and to complete a new form annually thereafter. In addition, members are reminded to report any new issues that arise outside of the annual disclosure period. The disclosure forms are reviewed by path's general counsel, and, if any actual or potential conflicts are identified, general counsel makes a recommendation to the chair of the governance committee and the chair of the board for a management plan to properly manage any conflicts. A formal management plan is then agreed upon with the board member, and the entire board of directors is informed at the next regularly scheduled board meeting.”

Form 990, Part VI, Section C, Line 19

“Pds makes its governing documents, conflict of interest policy, and financial statements available to the public upon request.”

Filing and Contact Details

Filer

Filer Name
Path Drug Solutions
EIN
94-3384500
Phone
2062853500
Address
2201 WESTLAKE AVENUE NO 200, SEATTLE, WA 98121

Signing Officer

Name
Olivia D Polius
Title
Chief Financial Officer
Phone
2062853500
Signed
2016-11-11
Discuss with paid preparer
Yes

Organization Details

Principal Officer
Olivia D Polius
Formed
2000
Legal Domicile
CA
Voting Board Members
8
Independent Board Members
3
Employees
0
Volunteers
0

Preparer

Firm
Gelman Rosenberg & Freedman
Address
4550 MONTGOMERY AVE SUITE 650N, BETHESDA, MD 20814-2930
Phone
3019519090
Supplemental Narrative

Additional Explanations

FORM 990, PART XI, LINE 9:

“From time to time, unspent award funds (or unused obligations) may be returned to a funder for a variety of reasons including, but not limited to, early termination of a project by a funder, or a reduction in funds required to accomplish a project's scope of work. -24,293,835.”

Raw XML AppendixShowing 400 of 652 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990/AccountantCompileOrReviewInd00
IRS990/AccountsPayableAccrExpnssGrp/BOYAmt01584692
IRS990/AccountsPayableAccrExpnssGrp/EOYAmt01605303
IRS990/AccountsReceivableGrp/BOYAmt0707
IRS990/AccountsReceivableGrp/EOYAmt01933
IRS990/ActivitiesConductedPrtshpInd00
IRS990/ActivityOrMissionDesc0SEE PART III, LINE 1.
IRS990/AdvertisingGrp/ProgramServicesAmt01789
IRS990/AdvertisingGrp/TotalAmt01789
IRS990/AllOtherContributionsAmt06310419
IRS990/AllOtherExpensesGrp/ProgramServicesAmt01105
IRS990/AllOtherExpensesGrp/TotalAmt01105
IRS990/AnnualDisclosureCoveredPrsnInd01
IRS990/AuditCommitteeInd01
IRS990/BooksInCareOfDetail/BusinessName/BusinessNameLine1Txt0OLIVIA POLIUS CHIEF FINANCIAL OFFICER
IRS990/BooksInCareOfDetail/PhoneNum02062853500
IRS990/BooksInCareOfDetail/USAddress/AddressLine1Txt02201 WESTLAKE AVENUE SUITE 200
IRS990/BooksInCareOfDetail/USAddress/CityNm0SEATTLE
IRS990/BooksInCareOfDetail/USAddress/StateAbbreviationCd0WA
IRS990/BooksInCareOfDetail/USAddress/ZIPCd098121
IRS990/BusinessRlnWithFamMemInd00
IRS990/BusinessRlnWithOfficerEntInd00
IRS990/BusinessRlnWithOrgMemInd00
IRS990/CashNonInterestBearingGrp/BOYAmt051703
IRS990/CashNonInterestBearingGrp/EOYAmt049655
IRS990/ChangeToOrgDocumentsInd00
IRS990/CntrctRcvdGreaterThan100KCnt00
IRS990/CollectionsOfArtInd00
IRS990/CompensationFromOtherSrcsInd00
IRS990/CompensationProcessCEOInd00
IRS990/CompensationProcessOtherInd00
IRS990/ConferencesMeetingsGrp/ProgramServicesAmt057763
IRS990/ConferencesMeetingsGrp/TotalAmt057763
IRS990/ConflictOfInterestPolicyInd01
IRS990/ConservationEasementsInd00
IRS990/ConsolidatedAuditFinclStmtInd01
IRS990/CreditCounselingInd00
IRS990/CYBenefitsPaidToMembersAmt00
IRS990/CYContributionsGrantsAmt07126779
IRS990/CYGrantsAndSimilarPaidAmt04768944
IRS990/CYInvestmentIncomeAmt012936
IRS990/CYOtherExpensesAmt01228767
IRS990/CYOtherRevenueAmt00
IRS990/CYProgramServiceRevenueAmt00
IRS990/CYRevenuesLessExpensesAmt01142004
IRS990/CYSalariesCompEmpBnftPaidAmt00
IRS990/CYTotalExpensesAmt05997711
IRS990/CYTotalFundraisingExpenseAmt00
IRS990/CYTotalProfFndrsngExpnsAmt00
IRS990/CYTotalRevenueAmt07139715
IRS990/DecisionsSubjectToApprovaInd00
IRS990/DeductibleArtContributionInd00
IRS990/DeductibleNonCashContriInd00
IRS990/DelegationOfMgmtDutiesInd00
IRS990/DepreciationDepletionGrp/ManagementAndGeneralAmt06706
IRS990/DepreciationDepletionGrp/TotalAmt06706
IRS990/Desc0WORKING THROUGH CROSS-SECTOR PARTNERSHIPS, PDS ADVANCED DRUG RESEARCH AND DEVELOPMENT TO COMBAT TOP GLOBAL HEALTH THREATS TO WOMEN AND CHILDREN IN 2015. PRODUCT DEVELOPMENT: WORK TO STOP MALARIA CONTINUED WITH SHIPMENT OF 51 MILLION ANTIMALARIAL TREATMENTS MADE USING SEMISYNTHETIC ARTEMISININ (SSART) TO MORE THAN 20 COUNTRIES ACROSS SUB-SAHARAN AFRICA. SSART-WHICH WAS DEVELOPED AND SCALED UP BY A GLOBAL PARTNERSHIP INVOLVING PDS-COMPLEMENTS THE BOTANICAL SUPPLY OF ARTEMISININ, HELPING TO STRENGTHEN THE SUPPLY CHAIN FOR ANTIMALARIAL TREATMENTS AND STABILIZE PRICING. ALSO, THE AVAILABILITY OF SSART INCREASES ACCESS TO TREATMENT FOR THE MILLIONS SICKENED BY MALARIA EVERY YEAR, OFTEN YOUNG CHILDREN IN AFRICA. WE ALSO PARTNERED WITH THE CLINTON HEALTH ACCESS INITIATIVE TO FURTHER STABILIZE ARTEMISININ MARKETS BY DEVELOPING PROJECTIONS FOR FUTURE SUPPLY AND DEMAND. THIS WORK INCLUDED ASSESSING THE RATIONALE FOR AN SSART RESERVE AND ESTIMATING THE AMOUNT THAT WOULD BE NEEDED FOR SUCH AN ENDEAVOR. WITH OUR GLOBAL PARTNERS, WE ALSO ADVANCED A LONG-ACTING INJECTABLE FORMULATION OF RILPIVIRINE, TMC278 LA, TO A PHASE 2 STUDY. THE PURPOSE OF THE STUDY WAS TO TEST THE SAFETY AND ACCEPTABILITY OF TMC278 LA FOR PREEXPOSURE PROPHYLAXIS (PREP). PREP IS A STRATEGY THAT INVOLVES USE OF ANTIRETROVIRAL MEDICATIONS TO REDUCE THE RISK OF HIV INFECTION IN HEALTHY, UNINFECTED ADULTS. CLINICAL TRIALS HAVE SHOWN THAT DAILY, ORAL PREP USING THE ANTIRETROVIRAL DRUGS TENOFOVIR AND EMTRICITABINE DRAMATICALLY REDUCES THE RISK OF HIV INFECTION FOR MEN AND WOMEN WHO TAKE IT AS DIRECTED. A LONG-ACTING FORMULATION OF PREP THAT REQUIRES LESS-FREQUENT DOSING HAS THE POTENTIAL TO IMPROVE UPTAKE AND ADHERENCE. IT WOULD ALSO EXPAND THE GLOBAL TOOLBOX OF PREVENTION INTERVENTIONS, PROVIDING SAFE AND EFFECTIVE CHOICES TO ADDRESS DIFFERENT CIRCUMSTANCES AND PREFERENCES. IN ADDITION, PDS WORKED IN 2015 TO ADVANCE THE DEVELOPMENT OF THERAPEUTICS TO BETTER ADDRESS DIARRHEAL DISEASE, A LEADING CAUSE OF ILLNESS AND DEATH AMONG YOUNG CHILDREN IN LOW-RESOURCE SETTINGS. PDS COLLABORATED WITH PARTNERS AT ERASMUS UNIVERSITY TO EVALUATE THE POTENTIAL EFFICACY OF DIARRHEAL DISEASE DRUG CANDIDATES USING HUMAN INTESTINAL BIOPSY TISSUE. APPROVAL FOR THESE STUDIES WAS OBTAINED FROM THE ERASMUS UNIVERSITY MEDICAL CENTER'S MEDICAL AND ETHICAL REVIEW COMMITTEE.
IRS990/DescribedInSection501c3Ind01
IRS990/DisregardedEntityInd00
IRS990/DocumentRetentionPolicyInd01
IRS990/DonorAdvisedFundInd00
IRS990/ElectionOfBoardMembersInd00
IRS990/EmployeeCnt00
IRS990/EngagedInExcessBenefitTransInd00
IRS990/ExpenseAmt05004556
IRS990/FamilyOrBusinessRlnInd00
IRS990/FederalGrantAuditRequiredInd00
IRS990/FeesForServicesLegalGrp/ProgramServicesAmt04504
IRS990/FeesForServicesLegalGrp/TotalAmt04504
IRS990/FeesForServicesOtherGrp/ManagementAndGeneralAmt012000
IRS990/FeesForServicesOtherGrp/ProgramServicesAmt0112777
IRS990/FeesForServicesOtherGrp/TotalAmt0124777
IRS990/ForeignActivitiesInd01
IRS990/ForeignCountryCd0IN
IRS990/ForeignFinancialAccountInd01
IRS990/ForeignGrantsGrp/ProgramServicesAmt0147024
IRS990/ForeignGrantsGrp/TotalAmt0147024
IRS990/ForeignOfficeInd01
IRS990/Form8282PropertyDisposedOfInd00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt039.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt139.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt239.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt339.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt439.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt50.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt60.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRltdOrgRt70.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt01.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt11.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt21.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt31.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt41.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt52.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt62.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt72.00
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd0X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd1X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd2X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd3X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd4X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd5X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd6X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd7X
IRS990/Form990PartVIISectionAGrp/OfficerInd0X
IRS990/Form990PartVIISectionAGrp/OfficerInd1X
IRS990/Form990PartVIISectionAGrp/OfficerInd2X
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt059038
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt146727
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt239328
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt358018
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt436507
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt50
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt60
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt70
IRS990/Form990PartVIISectionAGrp/PersonNm0STEPHEN B DAVIS
IRS990/Form990PartVIISectionAGrp/PersonNm1OLIVIA D POLIUS
IRS990/Form990PartVIISectionAGrp/PersonNm2DANIEL LASTER
IRS990/Form990PartVIISectionAGrp/PersonNm3DAVID C KASLOW
IRS990/Form990PartVIISectionAGrp/PersonNm4JORGE FLORES
IRS990/Form990PartVIISectionAGrp/PersonNm5KEITH CHIRGWIN
IRS990/Form990PartVIISectionAGrp/PersonNm6KEN DUNCAN
IRS990/Form990PartVIISectionAGrp/PersonNm7DAN HARTMAN
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt00
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt10
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt20
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt30
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt40
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt50
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt60
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt70
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt0607729
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt1264997
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt2268812
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt3316540
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt4243396
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt50
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt60
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt70
IRS990/Form990PartVIISectionAGrp/TitleTxt0PRESIDENT & CEO
IRS990/Form990PartVIISectionAGrp/TitleTxt1TREASURER & CFO
IRS990/Form990PartVIISectionAGrp/TitleTxt2SECRETARY
IRS990/Form990PartVIISectionAGrp/TitleTxt3DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt4DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt5DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt6DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt7DIRECTOR
IRS990/Form990ProvidedToGvrnBodyInd01
IRS990/FormationYr02000
IRS990/FormerOfcrEmployeesListedInd00
IRS990/FSAuditedBasisGrp/ConsolidatedBasisFinclStmtInd0X
IRS990/FSAuditedInd01
IRS990/FundraisingActivitiesInd00
IRS990/GainOrLossGrp/OtherAmt0-3448
IRS990/GamingActivitiesInd00
IRS990/GoverningBodyVotingMembersCnt08
IRS990/GrantAmt04270566
IRS990/GrantsToDomesticOrgsGrp/ProgramServicesAmt04621920
IRS990/GrantsToDomesticOrgsGrp/TotalAmt04621920
IRS990/GrantsToIndividualsInd00
IRS990/GrantsToOrganizationsInd01
IRS990/GrantToRelatedPersonInd00
IRS990/GrossReceiptsAmt07143163
IRS990/GroupReturnForAffiliatesInd00
IRS990/IncludeFIN48FootnoteInd00
IRS990/IndependentAuditFinclStmtInd00
IRS990/IndependentVotingMemberCnt03
IRS990/IndivRcvdGreaterThan100KCnt00
IRS990/IndoorTanningServicesInd00
IRS990/InfoInScheduleOPartIIIInd0X
IRS990/InfoInScheduleOPartVIInd0X
IRS990/InfoInScheduleOPartXIInd0X
IRS990/InformationTechnologyGrp/ProgramServicesAmt03207
IRS990/InformationTechnologyGrp/TotalAmt03207
IRS990/InsuranceGrp/ManagementAndGeneralAmt01676
IRS990/InsuranceGrp/ProgramServicesAmt07249
IRS990/InsuranceGrp/TotalAmt08925
IRS990/InvestmentIncomeGrp/ExclusionAmt016384
IRS990/InvestmentIncomeGrp/TotalRevenueColumnAmt016384
IRS990/InvestmentInJointVentureInd00
IRS990/InvestmentsPubTradedSecGrp/BOYAmt03904
IRS990/InvestmentsPubTradedSecGrp/EOYAmt03736
IRS990/IRPDocumentCnt00
IRS990/IRPDocumentW2GCnt00
IRS990/LandBldgEquipAccumDeprecAmt093107
IRS990/LandBldgEquipBasisNetGrp/BOYAmt021856
IRS990/LandBldgEquipBasisNetGrp/EOYAmt010020
IRS990/LandBldgEquipCostOrOtherBssAmt0103127
IRS990/LegalDomicileStateCd0CA
IRS990/LessCostOthBasisSalesExpnssGrp/OtherAmt03448
IRS990/LoanOutstandingInd00
IRS990/LobbyingActivitiesInd00
IRS990/LocalChaptersInd00
IRS990/MaterialDiversionOrMisuseInd00
IRS990/MembersOrStockholdersInd00
IRS990/MethodOfAccountingAccrualInd0X
IRS990/MinutesOfCommitteesInd01
IRS990/MinutesOfGoverningBodyInd01
IRS990/MissionDesc0PATH DRUG SOLUTIONS (PDS) DEVELOPS AND ADVANCES SAFE AND EFFECTIVE MEDICINES FOR THE PREVENTION AND TREATMENT OF DISEASES DISPROPORTIONATELY AFFECTING WOMEN AND CHILDREN IN LOW-RESOURCE SETTINGS. WE WORK WITH A VARIETY OF PUBLIC- AND PRIVATE-SECTOR STAKEHOLDERS TO BUILD CROSS-SECTOR COLLABORATIONS, SECURE INTELLECTUAL PROPERTY, REVISIT PROMISING DRUGS OR DRUG CANDIDATES THAT HAVE BEEN SET ASIDE FOR NONMEDICAL REASONS (E.G., BECAUSE OF LACK OF EARNING POTENTIAL), AND HARNESS SCIENTIFIC AND MANUFACTURING CAPACITY IN HIGH- AND LOW- OR MIDDLE-INCOME COUNTRIES TO ENSURE DRUGS ARE AVAILABLE AND ACCESSIBLE TO ALL THOSE WHO NEED THEM.
IRS990/MoreThan5000KToIndividualsInd00
IRS990/MoreThan5000KToOrgInd01
IRS990/NetAssetsOrFundBalancesBOYAmt036393721
IRS990/NetAssetsOrFundBalancesEOYAmt013241721
IRS990/NetGainOrLossInvestmentsGrp/ExclusionAmt0-3448
IRS990/NetGainOrLossInvestmentsGrp/TotalRevenueColumnAmt0-3448
IRS990/NetUnrelatedBusTxblIncmAmt00
IRS990/NetUnrlzdGainsLossesInvstAmt0-169
IRS990/NondeductibleContributionsInd00
IRS990/OccupancyGrp/ManagementAndGeneralAmt0182552
IRS990/OccupancyGrp/TotalAmt0182552
IRS990/OfficeExpensesGrp/ManagementAndGeneralAmt0144
IRS990/OfficeExpensesGrp/ProgramServicesAmt054471
IRS990/OfficeExpensesGrp/TotalAmt054615
IRS990/OfficerMailingAddressInd00
IRS990/OperateHospitalInd00
IRS990/Organization501c3Ind0X
IRS990/OrganizationFollowsSFAS117Ind0X
IRS990/OtherChangesInNetAssetsAmt0-24293835
IRS990/OtherExpensesGrp/Desc0SUBCONTRACTS
IRS990/OtherExpensesGrp/Desc1EQUIPMENT R&M
IRS990/OtherExpensesGrp/Desc2LAB SUPPLIES
IRS990/OtherExpensesGrp/Desc3OFFSITE STORAGE
IRS990/OtherExpensesGrp/ManagementAndGeneralAmt0298
IRS990/OtherExpensesGrp/ManagementAndGeneralAmt11550
IRS990/OtherExpensesGrp/ProgramServicesAmt0389069
IRS990/OtherExpensesGrp/ProgramServicesAmt116345
IRS990/OtherExpensesGrp/ProgramServicesAmt25713
IRS990/OtherExpensesGrp/ProgramServicesAmt31468
IRS990/OtherExpensesGrp/TotalAmt0389069
IRS990/OtherExpensesGrp/TotalAmt116643
IRS990/OtherExpensesGrp/TotalAmt25713
IRS990/OtherExpensesGrp/TotalAmt33018
IRS990/OtherWebsiteInd0X
IRS990/PartialLiquidationInd00
IRS990/PayPremiumsPrsnlBnftCntrctInd00
IRS990/PledgesAndGrantsReceivableGrp/BOYAmt012038366
IRS990/PledgesAndGrantsReceivableGrp/EOYAmt02045216
IRS990/PoliticalCampaignActyInd00
IRS990/PrepaidExpensesDefrdChargesGrp/BOYAmt021081
IRS990/PrepaidExpensesDefrdChargesGrp/EOYAmt03352
IRS990/PrincipalOfficerNm0OLIVIA D POLIUS
IRS990/ProfessionalFundraisingInd00
IRS990/ProgSrvcAccomActy2Grp/Desc0INTERNATIONAL DEVELOPMENT: TO BUILD CLINICAL RESEARCH CAPACITY IN INDIA, PDS WORKED IN 2015 TO FURTHER DEVELOP AND DESIGN A CLINICAL RESEARCH TRAINING AND MENTORSHIP PROGRAM. THIS WORK WAS DONE IN COLLABORATION WITH THREE NATIONAL CLINICAL RESEARCH RESOURCE CENTERS SPECIALIZING IN PHARMACOVIGILANCE, RESEARCH ETHICS, AND DATA MANAGEMENT.IN ADDITION, PDS ADVANCED WORK ON THE ADOPTION OF PAROMOMYCIN INTRAMUSCULAR INJECTION (PMIM) BY THE GOVERNMENTS OF BANGLADESH AND NEPAL FOR THE TREATMENT OF VISCERAL LEISHMANIASIS (VL), ALSO KNOWN AS KALA-AZAR, WHICH IS A NEGLECTED INFECTIOUS DISEASE THAT AFFECTS TENS OF THOUSANDS EACH YEAR. PMIM IS AN EFFECTIVE AND SAFE TREATMENT FOR THE DISEASE AND HAS SOME ADVANTAGES OVER OTHER THERAPIES. MOREOVER, PDS BUILT CAPACITY WITHIN BANGLADESH AND NEPAL TO CARRY OUT FOCUSED PHARMACOVIGILANCE STUDIES FOR DRUGS USED IN VL AND POST KALA-AZAR DERMAL LEISHMANIASIS (PKDL) TO ENSURE THEIR SAFETY. PDS ALSO CONDUCTED A STUDY ON THE FREQUENCY OF PKDL AMONG VL PATIENTS TREATED WITH MONOTHERAPY OR COMBINATION THERAPY IN BANGLADESH TO DETERMINE WHICH TREATMENT BEST PREVENTS SUBSEQUENT ILLNESS.
IRS990/ProgSrvcAccomActy2Grp/ExpenseAmt0788229
IRS990/ProgSrvcAccomActy2Grp/GrantAmt0498378
IRS990/ProhibitedTaxShelterTransInd00
IRS990/PYBenefitsPaidToMembersAmt00
IRS990/PYContributionsGrantsAmt05259668
IRS990/PYExcessBenefitTransInd00
IRS990/PYGrantsAndSimilarPaidAmt06406305
IRS990/PYInvestmentIncomeAmt010438
IRS990/PYOtherExpensesAmt04353184
IRS990/PYOtherRevenueAmt00
IRS990/PYProgramServiceRevenueAmt00
IRS990/PYRevenuesLessExpensesAmt0-5489383
IRS990/PYSalariesCompEmpBnftPaidAmt00
IRS990/PYTotalExpensesAmt010759489
IRS990/PYTotalProfFndrsngExpnsAmt00
IRS990/PYTotalRevenueAmt05270106
IRS990/QuidProQuoContributionsInd00
IRS990/RcvFndsToPayPrsnlBnftCntrctInd00
IRS990/ReconcilationRevenueExpnssAmt01142004
IRS990/RegularMonitoringEnfrcInd01
IRS990/RelatedEntityInd01
IRS990/RelatedOrganizationCtrlEntInd00
IRS990/RelatedOrganizationsAmt0816360
IRS990/ReportInvestmentsOtherSecInd00
IRS990/ReportLandBuildingEquipmentInd01
IRS990/ReportOtherAssetsInd00
IRS990/ReportOtherLiabilitiesInd00
IRS990/ReportProgramRelatedInvstInd00
IRS990/SavingsAndTempCashInvstGrp/BOYAmt025840796
IRS990/SavingsAndTempCashInvstGrp/EOYAmt012733112
IRS990ScheduleA/Form990SchASupportingOrgGrp/Contribution35ControlledInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/ContributionControllerInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/ContributionFamilyInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/ControlledDisqualifiedPrsnInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/DisqualifiedPrsnControllIntInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/DisqualifiedPrsnOwnrIntInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/ExcessBusinessHoldingsRulesInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/ListedByNameGoverningDocInd01
IRS990ScheduleA/Form990SchASupportingOrgGrp/LoanDisqualifiedPersonInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/OrganizationChangeSuprtOrgInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/PaymentSubstantialContribtrInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/SupportedOrgNotOrganizedUSInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/SupportedOrgSectionC456Ind00
IRS990ScheduleA/Form990SchASupportingOrgGrp/SupportNonSupportedOrgInd00
IRS990ScheduleA/Form990SchASupportingOrgGrp/SuprtOrgNoIRSDeterminationInd00
IRS990ScheduleA/Form990SchAType1SuprtOrgGrp/OperateBenefitNonSuprtOrgInd00
IRS990ScheduleA/Form990SchAType1SuprtOrgGrp/PowerAppointMajorityDirTrstInd01
IRS990ScheduleA/OtherSupportSumAmt00
IRS990ScheduleA/SupportedOrganizationsCnt01
IRS990ScheduleA/SupportedOrganizationsTotalCnt01
IRS990ScheduleA/SupportedOrgInformationGrp/EIN0911157127
IRS990ScheduleA/SupportedOrgInformationGrp/GoverningDocumentListedInd01
IRS990ScheduleA/SupportedOrgInformationGrp/OrganizationTypeCd07
IRS990ScheduleA/SupportedOrgInformationGrp/OtherSupportAmt00
IRS990ScheduleA/SupportedOrgInformationGrp/SupportAmt05997711
IRS990ScheduleA/SupportedOrgInformationGrp/SupportedOrganizationName/BusinessNameLine1Txt0PATH
IRS990ScheduleA/SupportingOrganization509a3Ind0X
IRS990ScheduleA/SupportingOrgType1Ind0X
IRS990ScheduleA/SupportSumAmt05997711
IRS990ScheduleB/ContributorInformationGrp/ContributorBusinessName/BusinessNameLine10RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorNum0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine10RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine20RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/City0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/State0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/ZIPCode0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/TotalContributionsAmt0RESTRICTED
IRS990/ScheduleBRequiredInd01
IRS990ScheduleD/EquipmentGrp/BookValueAmt010020
IRS990ScheduleD/EquipmentGrp/DepreciationAmt093107
IRS990ScheduleD/EquipmentGrp/OtherCostOrOtherBasisAmt0103127
IRS990ScheduleD/TotalBookValueLandBuildingsAmt010020
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt00
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt10
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt21
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt30
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt40
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt00
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt10
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt20
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt30
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt40
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt06141
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt1188556
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt2780
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt3276841
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt4147024
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt0EAST ASIA AND THE PACIFIC
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt1EUROPE
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt2SOUTH ASIA
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt3SOUTH ASIA
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt4SOUTH ASIA
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/SpecificServicesProvidedTxt0PRODUCT DEVELOPMENT
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/SpecificServicesProvidedTxt1PRODUCT DEVELOPMENT
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/SpecificServicesProvidedTxt2PRODUCT DEVELOPMENT
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/SpecificServicesProvidedTxt3INTERNATIONAL DEVELOPMENT
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt0PROGRAM SERVICES
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt1PROGRAM SERVICES
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt2PROGRAM SERVICES
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt3PROGRAM SERVICES
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt4GRANTMAKING
IRS990ScheduleF/BoycottCountriesInd00
IRS990ScheduleF/ContinuationSpentAmt00
IRS990ScheduleF/ContinutationTotalEmployeeCnt00
IRS990ScheduleF/ContinutationTotalOfficeCnt00
IRS990ScheduleF/ForeignCorpOwnershipInd00
IRS990ScheduleF/ForeignPartnershipInd00
IRS990ScheduleF/GrantRecordsMaintainedInd01
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt012214
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt149599
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt285211
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/MannerOfCashDisbursementTxt0CHECK/WIRE
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/MannerOfCashDisbursementTxt1CHECK/WIRE
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/MannerOfCashDisbursementTxt2CHECK/WIRE
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt0INTERNATIONAL DEVELOPMENT
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt1INTERNATIONAL DEVELOPMENT
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt2INTERNATIONAL DEVELOPMENT
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt0SOUTH ASIA
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt1SOUTH ASIA
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt2SOUTH ASIA
IRS990ScheduleF/InterestInForeignTrustInd00
IRS990ScheduleF/PassiveForeignInvestmestCoInd00
IRS990ScheduleF/SubtotalEmployeesCnt01
IRS990ScheduleF/SubtotalOfficesCnt00
IRS990ScheduleF/SubtotalSpentAmt0619342
IRS990ScheduleF/SupplementalInformationDetail/ExplanationTxt0SUBRECIPIENTS MUST SUBMIT PROGRESS REPORTS THAT ARE REVIEWED BY RESPONSIBLE PATH PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS OR FOLLOW UP ON ANY AREA OF CONCERN. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL AND FINANCIAL REPORTS. IN ADDITION, DISCRETIONARY ON-SITE VISITS ARE CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE PROGRAMMATIC OBJECTIVES OF THE PROJECT AND THE APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES.
IRS990ScheduleF/SupplementalInformationDetail/FormAndLineReferenceDesc0PART I, LINE 2:
IRS990ScheduleF/Total501c3OrgCnt03
IRS990ScheduleF/TotalEmployeeCnt01
IRS990ScheduleF/TotalOfficeCnt00
IRS990ScheduleF/TotalOtherOrgCnt00
IRS990ScheduleF/TotalSpentAmt0619342
IRS990ScheduleF/TransferToForeignCorpInd01
IRS990ScheduleI/GrantRecordsMaintainedInd01
IRS990ScheduleI/RecipientTable/CashGrantAmt0253110
IRS990ScheduleI/RecipientTable/CashGrantAmt145692
IRS990ScheduleI/RecipientTable/CashGrantAmt23835141
IRS990ScheduleI/RecipientTable/CashGrantAmt3487953
IRS990ScheduleI/RecipientTable/IRCSectionDesc0501(C)(3)
IRS990ScheduleI/RecipientTable/IRCSectionDesc1501(C)(3)
IRS990ScheduleI/RecipientTable/IRCSectionDesc2501(C)(3)
IRS990ScheduleI/RecipientTable/IRCSectionDesc3501(C)(3)
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt0PRODUCT DEVELOPMENT
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt1PRODUCT DEVELOPMENT
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt2GENERAL SUPPORT
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt3PRODUCT DEVELOPMENT
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt0ST LOUIS UNIVERSITY
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt1YALE UNIVERSITY
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt2PATH
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt3CLINTON HEALTH ACCESS INITIATIVE INC
IRS990ScheduleI/RecipientTable/RecipientEIN0430654872
IRS990ScheduleI/RecipientTable/RecipientEIN1060646973
IRS990ScheduleI/RecipientTable/RecipientEIN2911157127
IRS990ScheduleI/RecipientTable/RecipientEIN3271414646
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt03700 WEST PINE MALL SUITE 357
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt1PO BOX 1873
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt22201 WESTLAKE AVENUE SUITE 200
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt3383 DORCHESTER AVENUE SUITE 400

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings

Displayed year

2015 • Form 990Detailed filing. Detailed filing data is available for this year.

Open filing
Assets
$14,847,024
Liabilities
$1,605,303
Net assets
$13,241,721
Revenue
$7,139,715
Expenses
$5,997,711
Net income
$1,142,004
Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2018Detailed filing. Detailed filing data is available for this year.$0.00$0.00$0.00$2.97$3.58$0.60
2017Detailed filing. Detailed filing data is available for this year.$7.11$0.71$6.40$0.20$2.55$2.35
2016Detailed filing. Detailed filing data is available for this year.$10.2$0.05$10.2$0.22$3.28$3.06
2015Detailed filing. Detailed filing data is available for this year.$14.8$1.61$13.2$7.14$6.00$1.14
2014Detailed filing. Detailed filing data is available for this year.$38.0$1.58$36.4$5.27$10.8$5.49
2013Detailed filing. Detailed filing data is available for this year.$42.9$0.98$41.9$24.7$8.96$15.8
2012Facts available. Structured filing facts are available, but richer extracted sections are limited.$29.0$2.88$26.1$11.7
2011Facts available. Structured filing facts are available, but richer extracted sections are limited.$24.3$1.58$22.7$13.7
2010Facts available. Structured filing facts are available, but richer extracted sections are limited.$26.2$4.44$21.8$17.8